2017 Basic Science Abstracts

GCOS2017-P2-010

New dexrazoxane derivatives – investigation of their protective effects on a model of chronic anthracycline cardiotoxicity

Presenting Author: Miss. Petra Brazdova, PhD Student, Charles University, Hradec Kralove, Czech Republic

 

GCOS2017-P2-011

Molecular mechanisms underlying the vascular effects of cisplatin

Presenting Author: Dr. Alan Cameron, Clinical Research Fellow, University of Glasgow, Glasgow, United Kingdom

 

GCOS2017-P2-012

Vascular endothelial growth factor inhibitors (VEGFI) induce endothelial cell activation in cancer patients

Presenting Author: Dr. Alan Cameron, Clinical Research Fellow, University of Glasgow,Glasgow, United Kingdom

 

GCOS2017-P2-013

Label-free autofluorescence lifetime metrology to assess changes in myocardial fibrosis in vivo in a doxorubicin cardiomyopathy (DOX-HF) heart failure model

Presenting Author: Dr. Benjamin Dyer, Cardiology Specialist Registrar, London Deanery, London, United Kingdom    

 

GCOS2017-P2-014

Doxorubicin induces dose-dependent vascular diastolic dysfunction by up-regulating apoptosis and oxidative stress

Presenting Author: Miss. Jie Gu, Student, Dalian Medical University, Dalian, China

 

GCOS2017-P2-015

NH4CI Treatment Prevents doxorubicin induced myocardial dysfunction in mice meanwhile enhances doxorubicin-induced apoptosis in HeLa cells

Presenting Author: Miss. Xin Huang, Student, Dalian Medical University, Dalian, China

 

GCOS2017-P2-016

Neoplasm associated serotonin secretion leads to cardiac dysfunction, accompanied by pathological increase of cardiac biomarkers

Presenting Author: Dr. Ajith Kantharajah, Physician/Intern, Department of Cardiology, University of Heidelberg, Heidelberg, Germany

 

GCOS2017-P2-017

LCZ 696, administered during doxorubicin, trastuzumab and pertuzumab treatment, prevents cardiotoxicity in vitro model.

Presenting Author: Dr. Nicola Maurea, Chief, Division of Cardiology, National Cancer Institute, Sen. Pascale Foundation, Naples, Italy

 

GCOS2017-P2-018

Trastuzumab cardiomyopathy is prevented by the administration of ranolazine at the end of antineoplastic treatment: in vitro and in vivo study

Presenting Author: Dr. Nicola Maurea, Chief, Division of Cardiology, National Cancer Institute, Sen. Pascale Foundation, Naples, Italy

 

GCOS2017-P2-019

Insulin supplementation reduces cancer-induced cardiac atrophy and tumor volume

Presenting Author: Mr. Stefan Pietzsch, PhD Student, Medical Highschool of Hanover, Hannover, Germany

 

GCOS2017-P2-020

Are ACEi able to provide effective and sustained protection against chronic anthracycline cardiotoxicity in vivo

Presenting Author: Miss. Zuzana Pokorna, PhD Student, Charles University, Hradec Kralove, Czech Republic

 

GCOS2017-P2-021

Hyperpolarized 13C magnetic resonance spectroscopy reveals real-time metabolic flux changes in a rat model of doxorubicin-induced cardiotoxicity

Presenting Author: Dr. Kerstin Timm, Postdoctoral Research Fellow, Oxford University, Oxford, United Kingdom

 

GCOS2017-P2-022

Psychosocial stress exacerbates cardiac fibrosis in adult mice pre-exposed to doxorubicin as juveniles

Presenting Author: Dr. Beshay Zordoky, Assistant Professor, University of Minnesota, Minneapolis, MN, USA